Long-term Treatment of Proximal Deep Vein Thrombosis with Micronized Purified Flavonoid Fraction Additionally to Oral Rivaroxaban Improves Clinical and Ultrasound Outcomes
نویسندگان
چکیده
منابع مشابه
Remarkable regression of massive deep vein thrombosis in response to intensive oral rivaroxaban treatment
Deep vein thrombosis (DVT) is a common disease and is associated with pulmonary embolism (PE). Proximal iliofemoral DVT may lead to severe PE and chronic venous insufficiency. The standard therapy for DVT is anticoagulant therapy using heparin and a vitamin K antagonist, but a recent clinical study showed that rivaroxaban, an oral Xa inhibitor, was comparable to standard therapy and had less bl...
متن کاملLong-term outcome of transfemoral thrombectomy in patients with acute iliofemoral vein thrombosis
Abstract Background: The optimal therapy of acute iliofemoral venous thrombosis is still a matter of debate. The purpose of our study was to evaluate the late results of iliofemoral thrombectomy with regard to the prevention of the development of a Post Thrombotic Syndrome (PTS). Methods: During 2000-2003, 18 patients underwent transfemoral venous thrombectomy for acute iliofemoral venous thro...
متن کاملDeterminants of early and long-term efficacy of catheter-directed thrombolysis in proximal deep vein thrombosis.
PURPOSE Catheter-directed thrombolysis (CDT) for proximal deep vein thrombosis (DVT) effectively enhances clot removal and recently has been shown to reduce the development of postthrombotic syndrome (PTS). This study was performed to identify potential markers for early and long-term efficacy of CDT, adverse events, and their interrelationship. MATERIALS AND METHODS Patients aged 18-75 years...
متن کاملTreatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study.
BACKGROUND An effective and safe oral anticoagulant that needs no monitoring for dose adjustment is urgently needed for the treatment of diseases that require long-term anticoagulation. Rivaroxaban (BAY 59-7939) is an oral direct factor Xa inhibitor currently under clinical development. METHODS AND RESULTS This randomized, parallel-group phase II trial in patients with proximal deep-vein thro...
متن کاملEffects of Rivaroxaban on Coagulation Assays in Patients with Small Pulmonary Embolism and Deep Vein Thrombosis in Relation to Body Mass Index
Introduction: Rivaroxaban is a new anticoagulant medication for pulmonary thromboembolism (PTE) and deep vein thrombosis (DVT). There are limited data on the effect of body mass index (BMI) on the pharmacokinetics of rivaroxaban. This study aimed to assess the effect of rivaroxaban on coagulation assays in relation to BMI in PTE and DVT patients. Materials and Met...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European Journal of Vascular and Endovascular Surgery
سال: 2019
ISSN: 1078-5884
DOI: 10.1016/j.ejvs.2019.06.863